Case Report

Carnitine Deficiency after Long-Term Continuous Renal Replacement Therapy

Caroline Van de Wyngaert,1 Joseph P. Dewulf,2 Christine Collienne,1 Pierre-François Laterre,1 and Philippe Hantson1,3

1Department of Intensive Care, Cliniques St-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium
2Department of Clinical Chemistry, Cliniques St-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium
3Louvain Centre for Toxicology and Applied Pharmacology, Université Catholique de Louvain, 1200 Brussels, Belgium

Correspondence should be addressed to Philippe Hantson; philippe.hantson@uclouvain.be

Received 17 March 2022; Accepted 11 July 2022; Published 17 August 2022

Academic Editor: Chiara Lazzeri

Copyright © 2022 Caroline Van de Wyngaert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 60-year-old man was admitted in the intensive care unit (ICU) for a rapidly progressive respiratory failure due to SARS-CoV-2 infection. He developed numerous complications including acute kidney injury (AKI) requiring prolonged continuous renal replacement therapy (CRRT). Enteral feeding was initiated on day 8. Despite nutritional management, there was a remarkable amyotrophy and weight loss. On day 85 in the ICU, the patient became progressively unresponsive. An extensive metabolic workup was performed, and blood results showed hyperammoniemia and hypertriglyceridemia. Plasma free carnitine level was low, as was also copper. After carnitine supplementation, the neurological condition rapidly improved, and metabolic perturbations regressed. Prolonged CRRT may be complicated by clinically significant deficiency in micronutrients and trace elements.

1. Introduction

During the recent COVID-19 pandemic, the incidence of acute kidney injury was particularly high, and numerous patients required prolonged renal replacement therapy (RRT) [1]. Among the unusual complications of continuous renal replacement therapy (CRRT), deficiency in some micronutrients may be of concern [2, 3].

We report a case of secondary carnitine deficiency following CRRT of a particularly long duration.

2. Case Description

A 60-year-old man (84 kg body weight, 25.1 kg/m² body mass index) with no medical past history was admitted in the intensive care unit (ICU) on November 2021, 9 for progressive respiratory failure due to SARS-CoV-2 infection. He rapidly required orotracheal intubation for mechanical ventilation. The clinical course was characterized by early complications including atrial fibrillation and arterial thrombosis in the right forearm. Enteral nutrition was initiated from day 8 via a nasogastric tube. It consisted of Fresubin® HP Energy (1.5 kcal/mL) (Fresenius Kabi, Belgium), containing: lipids 5.8 g/100 mL, carbohydrates 16.2 g/100 mL, proteins 7.5 g/100 mL, zinc 12 mg/100 mL, copper 130 μg/100 mL, and selenium 6.7 μg/100 mL. More specifically, this diet was containing 0.66 g/100 mL of lysine and 0.23 g/100 mL of methionine as potential precursors of carnitine. The mean daily caloric intake was 1472 kcal over the first two months (excluding glucose intake from basal dextrose infusion and lipid intake related to sedation with propofol). The patient was also regularly supplemented in thiamine, vitamin K, hydroxocobalamin, iron, and folate. He never received any medication (valproate, phenytoin) known to lower carnitine levels. There was also no recent infection by urease-producing bacteria.

After the development of oliguria and acute renal failure, continuous venovenous hemofiltration (CVVH) was started...
from day 41. Regional citrate anticoagulation was administered before the filter (AN-69®; 0.6 m²), and the predilution and postfilter fluid flow with Prismocal® was 1000 mL/h each; hemofiltration rate was adapted to maintain a negative fluid balance.

Physical examination revealed an impressive weight (-14 kg) and muscle loss. The patient was found poorly responsive to verbal or painful stimulation 44 days after the start of CVVH. The electroencephalogram (EEG) revealed diffuse slowing (5 Hz), with predominant theta and delta waves. Toxic encephalopathy was suspected and plasma ammonia concentration peaked at 148 μg/dL (<90).

In parallel, there was a significant increase in LDH, AST, and triglycerides (Figure 1). By contrast, there was no significant change in liver function tests nor evidence for hemolysis.

Among trace elements, plasma copper level was 32 μg/dL (70-140), zinc 83 μg/dL (70-120), iron 23 μg/dL (33-193), and selenium 8.3 μg/dL (5-15).

The plasma acylcarnitine profile revealed an important decrease in free carnitine at 3.2 μmol/L (16-63). Total amount of carnitine was also very low at 7.96 μmol/L (18-84). Intravenous L-carnitine was administered (100 mg/kg over 6 days) (February 2, 2022) and resulted in a rapid improvement of the patient’s neurological condition, together with the decrease of ammonia and triglycerides level. Over the following weeks, a significant progress in the weaning from the ventilator was also noted. Free and total plasma carnitine levels were restored at 34.5 and 57.88 μmol/L, respectively; in the ultrafiltrate, the concentration of free carnitine was 31.7 μmol/L. Blood was sampled from the inflow and outflow line of the dialysis circuit, while the patient was receiving a daily supplemental dose of 1 g carnitine. Extraction of plasma carnitine by the circuit was calculated as: \( \frac{1}{2} \frac{[\text{carnitine}]_{\text{IN}} - [\text{carnitine}]_{\text{OUT}}}{[\text{carnitine}]_{\text{IN}}} \). It corresponded to a plasma extraction of free carnitine of 93% (or 97% when expressed as total carnitine).

3. Discussion

Hemofiltration as a mode of CRRT may cause a negative balance in some trace elements and micronutrients, and the effects of prolonged continuous venovenous hemofiltration (CVVH) have been poorly investigated to date [4, 5]. In the studies measuring trace elements during RRT, copper, selenium, and zinc losses were the most frequently reported [6]. In a prospective study on 31 critically ill patients requiring CRRT, clinically evident losses of copper, iron, selenium, and zinc, as well thiamine and folate, were documented [7]. Our patient had a relatively low plasma copper level, but normal zinc and selenium levels, with the limitation that only a single determination was obtained.
Copper is an essential element required as a cofactor in numerous enzymatic processes. According to some recommendations, the daily dietary intake in an adult should be higher than 2 mg [8]. The effect of copper deficiency on lipid metabolism, including an elevation of plasma lipids (total cholesterol, triglycerides, and phospholipids), has been well documented experimentally [9]. In addition, other complications of copper deficiency include hematologic, neurologic and metabolic disorders, impaired immunity, and heart function.

Carnitine not obtained from food is synthesized endogenously from two essential amino acids, lysine, and methionine. This occurs in the kidney, liver, and brain. Cardiac and skeletal muscle must acquire carnitine from plasma. Carnitine plays a key role in energy metabolism via the transport of long-chain fatty acids from the mitochondrial intermembrane space into the mitochondrial matrix for beta-oxidation in cardiac and skeletal myocytes [10, 11]. Secondary, low plasma carnitine has been observed in critically ill patients with trauma, sepsis, acute organ failure, poor nutritional status, or some drug therapy (e.g., valproate) and has been associated with prolonged ICU stay [12, 13]. Severe muscle atrophy as seen in some ICU patients with prolonged stay could also reduce carnitine stores. In addition, patients receiving long-term feeding with low levels of L-carnitine are also exposed to carnitine deficiency [14, 15]. Carnitine deficiency may be followed by impaired oxidation of fatty acids, impaired immune function, but also altered ventilatory response. The etiology of carnitine deficiency in patients with acute kidney injury (AKI) requiring RRT is likely multifactorial: decreased synthesis due to effluent losses of metabolic precursors (ascorbic acid, amino acids), inadequate dietary intake, or carnitine effluent losses, even if this latter role is still debated [7, 16–18]. Carnitine deficiency may occur with CRRT duration as short as 5-7 days. As shown by this observation, a significant amount of carnitine could be lost in the ultrafiltrate. However, there is no firm recommendation regarding carnitine supplementation in patients receiving CRRT for a prolonged period. In a more chronic setting, a dialysis-related carnitine disorder usually combines anemia, intradialytic hypotension, cardiac cachexia, and skeletal muscle dysfunction [19]. Hyperammonemia with encephalopathy is also a potential consequence of carnitine deficiency [20, 21]. Indeed, carnitine is also indirectly required for the proper functioning of the urea cycle. When the beta-oxidation is impaired, availability of acetyl-CoA is decreased together with N-acetyl glutamic acid (NAGA), a critical allosteric regulator of carbamyl phosphate synthetase (CPS-1) activity, resulting in a reduced ammonia clearance. In the present observation, carnitine repletion resulted in a rapid improvement of the patient’s neurological condition, together with a decrease in ammonia and triglycerides levels. This would suggest that the role of copper deficiency on impaired fatty acid oxidation was probably modest. Even if there was some discrepancy between CK and AST, LDH levels, muscular injury was a probable complication of acquired carnitine deficiency.

Finally, our patient was initially admitted for a severe COVID-19 pneumonia. The profile of trace elements including zinc, copper, and selenium has been analyzed in COVID-19 patients, but without evidence for a COVID-19-related copper deficiency [22]. Additionally, changes in lipid metabolism have been investigated in COVID-19 patients, but no correlation between carnitine and COVID-19 has been explored [23].

In summary, carnitine deficiency may contribute to sarcopenia and prolonged weaning time from mechanical ventilation in critically ill patients. This case illustrates that the combination of long-term enteral feeding and CRRT may expose the patient to a significant risk of trace elements and micronutrient deficiencies. This could imply a need for closer monitoring and potential supplementation. Awaiting for further prospective and controlled-trials, a possible supplement-level dosing strategy for carnitine would be in the range of 0.5 to 1 g/day for the patients combining long-term tube feeding and CRRT exceeding at least one week.

**Consent**

Written informed consent has been obtained from the patient’s relatives.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] R. S. Shemies, E. Nagy, D. Younis, and H. Sheashaa, “Renal replacement therapy for critically ill patients with COVID-19-associated acute kidney injury: a review of current knowledge,” *Therapeutic Apheresis and Dialysis*, vol. 26, no. 1, pp. 15–23, 2022.

[2] M. Tonelli, N. Wiebe, A. Bello et al., “Concentrations of trace elements and clinical outcomes in hemodialysis patients,” *Clinical Journal of the American Society of Nephrology*, vol. 13, no. 6, pp. 907–915, 2018.

[3] D. A. Story, C. Ronco, and R. Bellomo, “Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous hemofiltration,” *Critical Care Medicine*, vol. 27, no. 1, pp. 220–223, 1999.

[4] N. Ben-Hamouda, M. Charrière, P. Voirol, and M. M. Berger, “Massive copper and selenium losses cause life-threatening deficiencies during prolonged continuous renal replacement,” *Nutrition*, vol. 34, pp. 71–75, 2017.

[5] M. D. Churchwell, D. A. Pasko, I. F. Btaiche, J. C. Jain, and B. A. Mueller, “Trace element removal during in vitro and in vivo continuous haemodialysis,” *Nephrology, Dialysis, Transplantation*, vol. 22, no. 10, pp. 2970–2977, 2007.

[6] M. M. Berger, M. Broman, L. Forni, M. Ostermann, E. De Waele, and P. E. Wischmeyer, “Nutrients and micronutrients at risk during renal replacement therapy: a scoping review,” *Current Opinion in Critical Care*, vol. 27, no. 4, pp. 367–377, 2021.

[7] M. Ostermann, J. Summers, K. Lei et al., “Micronutrients in critically ill patients with severe acute kidney injury - a prospective study,” *Scientific Reports*, vol. 10, no. 1, p. 1505, 2020.

[8] B. Blades, S. Ayton, Y. H. Hung, A. I. Bush, and S. La Fontaine, “Copper and lipid metabolism: a reciprocal relationship,”
[9] A. Morrell, S. Tallino, L. Yu, and J. L. Burkhead, “The role of insufficient copper in lipid synthesis and fatty-liver disease,” IUBMB Life, vol. 69, no. 4, pp. 263–270, 2017.

[10] J. L. Flanagan, P. A. Simmons, J. Vehige, M. D. Willcox, and Q. Garrett, “Role of carnitine in disease,” Nutrition & Metabolism, vol. 7, no. 1, p. 30, 2010.

[11] S. Ahmad, “L-carnitine in dialysis patients,” Seminars in Dialysis, vol. 14, no. 3, pp. 209–217, 2001.

[12] K. Sgambat and A. Moudgil, “Carnitine deficiency in children receiving continuous renal replacement therapy,” Hemodialysis International, vol. 20, no. 1, pp. 63–67, 2016.

[13] L. Bonafé, M. M. Berger, Y. A. Que, and J. I. Mechanick, “Carnitine deficiency in chronic critical illness,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 17, no. 2, pp. 200–209, 2014.

[14] P. Ling, D. J. Lee, E. M. Yoshida, and S. Sirrs, “Carnitine deficiency presenting with encephalopathy and hyperammonemia in a patient receiving chronic enteral tube feeding: a case report,” Journal of Medical Case Reports, vol. 6, no. 1, p. 227, 2012.

[15] N. Isse, Y. Miura, T. Obata, and N. Takahara, “Carnitine deficiency presenting with a decreased mental state in a patient with amyotrophic lateral sclerosis receiving long-term tube feeding: a case report,” Journal of Medical Case Reports, vol. 7, no. 1, p. 286, 2013.

[16] N. Lumlertgul, D. E. Bear, and M. Ostermann, “Clearance of micronutrients during continuous renal replacement therapy,” Critical Care, vol. 24, no. 1, p. 616, 2020.

[17] T. Bohmer, H. Bergrem, and K. Eiklid, “Carnitine deficiency induced during intermittent haemodialysis for renal failure,” Lancet, vol. 1, no. 8056, pp. 126–128, 1978.

[18] B. Schreiber, “Levocarnitine and dialysis: a review,” Nutrition in Clinical Practice, vol. 20, no. 2, pp. 218–243, 2005.

[19] G. Eknoyan, D. L. Latos, J. Lindberg, and National Kidney Foundation Carnitine Consensus Conference, “Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder,” American Journal of Kidney Diseases, vol. 41, no. 4, pp. 868–876, 2003.

[20] M. Cappe, P. Hantson, M. Komuta, M. F. Vincent, P. F. Laterre, and I. Ould-Nana, “Hyperammonemic encephalopathy and lipid dysmetabolism in a critically ill patient after a short course of amiodarone,” The Journal of Critical Care Medicine, vol. 5, no. 4, pp. 161–165, 2019.

[21] P. E. Lheureux and P. Hantson, “Carnitine in the treatment of valproic acid-induced toxicity,” Clinical Toxicology, vol. 47, no. 2, pp. 101–111, 2009.

[22] I. D. Ivanova, A. Pal, I. Simonelli et al., “Evaluation of zinc, copper, and Cu/Zn ratio in serum, and their implications in the course of COVID-19,” Journal of Trace Elements in Medicine and Biology, vol. 71, no. 71, article 126944, 2022.

[23] A. V. Sorokin, S. K. Karathanasis, Z. H. Yang, L. Freeman, K. Kotani, and A. T. Remaley, “COVID-19—associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches,” The FASEB Journal, vol. 34, no. 8, pp. 9843–9853, 2020.